Synchron Secures $200M Series D Funding to Advance Brain-Computer Interface for Paralysis

The funding comes amid growing activity in the brain-computer interface space, as companies pursue new approaches to restore communication and mobility for people with neurological conditions.

Synchron has raised $200 million in a Series D funding round to expand operations and advance the commercialization of its nonsurgical brain-computer interface (BCI) designed for people with paralysis.

The round was led by Double Point Ventures, with participation from existing investors Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Other participants included the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.

With this round, the New York-based medtech company has now raised a total of $345 million. The funding comes amid growing activity in the brain-computer interface space, as companies pursue new approaches to restore communication and mobility for people with neurological conditions.

Synchron’s Stentrode BCI system records and transmits neural signals to enable hands-free control of digital devices. Unlike traditional surgical implants, the company’s device is delivered to the motor cortex via the jugular vein through a minimally invasive catheter-like procedure.

So far, the device has been implanted in 10 patients with paralysis through clinical trials in the U.S. and Australia. In August, the company announced a milestone linking its BCI to an iPad, enabling a person with amyotrophic lateral sclerosis to navigate apps and write text using only thought. The same patient also used the device to operate an Apple Vision Pro headset and Amazon’s Alexa, performing everyday tasks such as turning on lights, making video calls, and playing music.

Synchron said the new funding will be used to accelerate pivotal trials, prepare for commercial launch, and expand its team of engineers and neuroscientists. The company also highlighted ongoing work in its cognitive artificial intelligence division in New York City and an engineering hub in San Diego focused on developing the next generation of brain interfaces.

“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said Tom Oxley, M.D., Ph.D., CEO and founder of Synchron. “This funding brings us closer to commercializing the Stentrode BCI platform, while accelerating the development of a breakthrough in the field—a next-generation transcatheter high-channel whole-brain interface.”

Stay tuned for more such updates on Digital Health News